1255 related articles for article (PubMed ID: 11081255)
1. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
5. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
6. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
7. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
[TBL] [Abstract][Full Text] [Related]
9. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
[TBL] [Abstract][Full Text] [Related]
10. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
[TBL] [Abstract][Full Text] [Related]
11. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
[TBL] [Abstract][Full Text] [Related]
12. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
13. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
15. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
17. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
[TBL] [Abstract][Full Text] [Related]
18. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
19. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy.
Ueta Y; Fukui H; Murakami H; Yamanouchi Y; Yamamoto R; Murao A; Santou Y; Taniguchi S; Mitani Y; Shigemasa C
Thyroid; 1999 Feb; 9(2):179-82. PubMed ID: 10090319
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of the 2nd generation assay for anti-TSH receptor antibodies to differentiate relapse of Graves' thyrotoxicosis from development of painless thyroiditis after antithyroid drug treatment for Graves' disease.
Izumi Y; Takeoka K; Amino N
Endocr J; 2005 Aug; 52(4):493-7. PubMed ID: 16127219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
